Today, Commerce Bank invests in Edwards Lifesciences Corp (EW) Shares

Today, Commerce Bank invests in Edwards Lifesciences Corp (EW) Shares
Commerce Bank boosted its stake in shares of Edwards Lifesciences Corp (NYSE:EW) by 3.4% during the third quarter, according to its most recent filing with the SEC. The firm owned 17,793 shares of the medical research company’s stock after buying an additional 585 shares during the period. Commerce Bank’s holdings in Edwards Lifesciences Corp were worth $2,145,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently added to or reduced their stakes in EW. Nelson Van Denburg & Campbell Wealth Management Group LLC bought a new position in shares of Edwards Lifesciences Corp during the second quarter worth approximately $100,000. Quadrant Capital Group LLC raised its stake in shares of Edwards Lifesciences Corp by 2.3% in the second quarter. Quadrant Capital Group LLC now owns 1,108 shares of the medical research company’s stock worth $106,000 after buying an additional 25 shares during the last quarter. Exane Derivatives acquired a new stake in shares of Edwards Lifesciences Corp during the second quarter worth about $118,000. Spirit of America Management Corp NY acquired a new stake in shares of Edwards Lifesciences Corp during the third quarter worth about $121,000. Finally, Duncker Streett & Co. Inc. raised its stake in shares of Edwards Lifesciences Corp by 10.5% in the second quarter. Duncker Streett & Co. Inc. now owns 1,264 shares of the medical research company’s stock worth $126,000 after buying an additional 120 shares during the last quarter. 83.99% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Edwards Lifesciences Corp (NYSE:EW) traded down 1.22% during trading on Friday, reaching $85.80. 2,022,939 shares of the company traded hands. Edwards Lifesciences Corp has a 52 week low of $72.20 and a 52 week high of $121.75. The company has a market capitalization of $18.35 billion, a price-to-earnings ratio of 33.91 and a beta of 0.71. The firm’s 50 day moving average price is $102.00 and its 200-day moving average price is $106.84.

Edwards Lifesciences Corp (NYSE:EW) last announced its quarterly earnings data on Tuesday, October 25th. The medical research company reported $0.68 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.68. Edwards Lifesciences Corp had a net margin of 19.24% and a return on equity of 24.32%. The company earned $739.40 million during the quarter, compared to analysts’ expectations of $749.14 million. During the same quarter in the prior year, the company earned $0.54 EPS. Edwards Lifesciences Corp’s revenue was up 20.1% compared to the same quarter last year. Equities analysts anticipate that Edwards Lifesciences Corp will post $2.88 EPS for the current fiscal year.

A number of equities research analysts have issued reports on EW shares. BTIG Research reiterated a “buy” rating and issued a $110.00 price target on shares of Edwards Lifesciences Corp in a research note on Friday, October 28th. Wells Fargo & Co. reiterated a “buy” rating on shares of Edwards Lifesciences Corp in a research note on Sunday, September 11th. Evercore ISI reiterated a “hold” rating and issued a $115.00 price target on shares of Edwards Lifesciences Corp in a research note on Friday, August 19th. Royal Bank Of Canada cut their price target on Edwards Lifesciences Corp from $130.00 to $123.00 and set an “outperform” rating for the company in a research note on Wednesday, October 26th. Finally, Leerink Swann reiterated a “buy” rating on shares of Edwards Lifesciences Corp in a research note on Friday, August 19th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-two have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $117.68.

In other news, VP Larry L. Wood sold 13,257 shares of the stock in a transaction that occurred on Monday, October 3rd. The shares were sold at an average price of $119.27, for a total value of $1,581,162.39. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Donald E. Bobo, Jr. sold 18,000 shares of the stock in a transaction that occurred on Friday, September 2nd. The shares were sold at an average price of $115.78, for a total transaction of $2,084,040.00. The disclosure for this sale can be found here. Corporate insiders own 2.37% of the company’s stock.

About Edwards Lifesciences Corp

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company manufactures heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. It develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting.

Related posts

Leave a Comment